Pipeline | OnKure, Inc.

Class-1/Class-4 HDAC inhibitor (OKI-179)

Immune checkpoint combinations

Solid tumor and heme cancers

Kinase inhibitor combinations

Solid tumor and heme cancers

Undisclosed Target (OKI-422)

Immune checkpoint combinations

Non Hodgkin’s Lymphoma

HDAC-6 inhibitor

Targeted therapy combinations

Solid and heme cancers